Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: A phase II study

Bone Marrow Transplantation

Volumn 30, Issue 12, 2002, Pages 879-884

  Viret, F ^a   Bertucci, F ^a,c   Genre, D ^a   Gravis, G ^a   Chabannon, C ^a   Conte, M ^b   Houvenaeghel, G ^a,c   Maraninchi, D ^a,c   Viens, P ^a,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b Hospital Ambroise Pare   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Advanced ovarian carcinoma; Sequential dose dense chemotherapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CD34 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MESNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LAPAROTOMY; LIVER INJURY; LIVER METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; SECOND LOOK SURGERY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FILGRASTIM; HEMATOLOGIC DISEASES; HUMANS; LIFE TABLES; MESNA; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NERVOUS SYSTEM DISEASES; PILOT PROJECTS; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036957334     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703762     Document Type: Article

References (29)

1. Cannistra S. Cancer of the ovary. New Engl J Med 1993; 329: 1550-1559.
2. Gershenson DM, Copeland LJ, Wharton JT et al. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 1985; 55: 1129-1135.
3. Omura GA, Bundy BN, Berek JS et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 457-465.
4. Neijt JP, ten Bokkel Huinink WW, van der Burg M et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157-1168.
5. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Eng J Med 1996; 334: 1-16.
6. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Nat Cancer Inst 2000; 92: 699-708.
7. Behrens BC, Hamilton TC, Masuda H et al. Characterization of a cis-diamminechloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987; 47: 414-418.
8. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756-767.
9. Levin L, Simon R, Hryniuk W. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst 1993; 85: 1732-1742.
10. Dauplat J, Legos M, Condat J et al. High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation. Gynecol Oncol 1989; 34: 294-298.
11. Bertucci F, Viens P, Delpero JR et al. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bone Marrow Transplant 2000; 26: 61-67.
12. Viens P, Maraninchi D, Legros M et al. High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 1990; 5: 227-233.
13. Legros M, Dauplat J, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III or IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302-1308.
14. Stiff PJ, Bayer R, Kerger C et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309-1317.
15. Stoppa AM, Bouabdallah R, Chabannon C et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 1722-1729.
16. Schilder RJ, Johnson S, Gallo J et al. Phase I trial of multiple cycles of chemotherapy supported by autologous peripheral-blood stem cells. J Clin Oncol 1999; 17: 2198-2207.
17. Aghajanian C, Fennely D, Shapiro F et al. Phase II study of 'dose-dense' high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16: 1852-1860.
18. Norton L. Kinetic concepts in the systemic drug therapy of breast cancer. Semin Oncol 1999; 26: 11-20.
19. Budman D, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 19: 1205-1211.
20. Chatelut E, Canal P, Brunner V et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Nat Cancer Institute 1995; 87: 573-580.
21. Chabannon C, Le Coroller AG, Faucher C et al. Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor. J Hematother 1995; 4: 171-179.
22. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1971; 53: 457-481.
23. Pierelli L, Perillo A, Greggi S et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol 1999; 17: 1288-1295.
24. Reiffers J, Cailliot C, Dazey B et al. Abrogation of post-myeloablative chemotherapy neutropenia by ex vivo expanded autologous CD34-positive cells. Lancet 1999; 354: 1092-1093.
25. Berek J. Epiththelial ovarian cancer. In: Berek JS, Hacker NF (eds). Practical Gynecologic Oncology. William & Wilkins: Baltimore, 1994, pp 327-382.
26. Rubin S, Randall T, Armstrong K et al. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999; 93: 21-24.
27. Wandt H, Birkmann J, Denzel T et al. Sequential cycles of high-dose chemotherapy with escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 1999; 23: 763-770.
28. Fennelly D, Schneider J, Spriggs D et al. Dose escaladation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 1995; 13: 1160-1166.
29. Cure H, Battista C, Guastalla J et al. Phase III randomized trial of high-dose chemotherapy and peripheral blood stem cell support as consolidation in patients with responsive low-burden advanced ovarian cancer: preliminary results of a GINECO/FNCLCC/ SFGM-TC study. Proc Am Soc Clin Oncol 2001; 20: 204a (Abstr. 815).